Literature DB >> 34697773

MicroRNA-7 Protects Against Neurodegeneration Induced by α-Synuclein Preformed Fibrils in the Mouse Brain.

Jie Zhang1, Mengyuan Zhao1, Run Yan1,2, Jun Liu1, Santhosh Maddila1, Eunsung Junn1, M Maral Mouradian3.   

Abstract

α-Synuclein is a key protein in the pathogenesis of Parkinson's disease as it accumulates in fibrillar form in affected brain regions. Misfolded α-synuclein seeds recruit monomeric α-synuclein to form aggregates, which can spread to anatomically connected brain regions, a phenomenon that correlates with clinical disease progression. Thus, downregulating α-synuclein levels could reduce seeding and inhibit aggregate formation and propagation. We previously reported that microRNA-7 (miR-7) protects neuronal cells by downregulating α-synuclein expression through its effect on the 3'-untranslated region of SNCA mRNA; however, whether miR-7 blocks α-synuclein seeding and propagation in vivo remains unknown. Here, we induced miR-7 overexpression in the mouse striatum unilaterally by infusing adeno-associated virus 1 (AAV-miR-7) followed by inoculation with recombinant α-synuclein preformed fibrils (PFF) a month later. Compared with control mice injected with non-targeting AAV-miR-NT followed by PFF, AAV-miR-7 pre-injected mice exhibited lower levels of monomeric and high-molecular-weight α-synuclein species in the striatum, and reduced amount of phosphorylated α-synuclein in the striatum and in nigral dopamine neurons. Accordingly, AAV-miR-7-injected mice had less pronounced degeneration of the nigrostriatal pathway and better behavioral performance. The neuroinflammatory reaction to α-synuclein PFF inoculation was also significantly attenuated. These data suggest that miR-7 inhibits the formation and propagation of pathological α-synuclein and protects against neurodegeneration induced by PFF. Collectively, these findings support the potential of miR-7 as a disease modifying biologic agent for Parkinson's disease and related α-synucleinopathies.
© 2021. The American Society for Experimental NeuroTherapeutics, Inc.

Entities:  

Keywords:  Parkinson’s disease; Pre-formed fibrils; microRNA-7; α-Synuclein; α-Synucleinopathies

Mesh:

Substances:

Year:  2021        PMID: 34697773      PMCID: PMC8804150          DOI: 10.1007/s13311-021-01130-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  64 in total

1.  Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections.

Authors:  Gregor Obernosterer; Javier Martinez; Mattias Alenius
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

2.  shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Authors:  Alevtina D Zharikov; Jason R Cannon; Victor Tapias; Qing Bai; Max P Horowitz; Vipul Shah; Amina El Ayadi; Teresa G Hastings; J Timothy Greenamyre; Edward A Burton
Journal:  J Clin Invest       Date:  2015-06-15       Impact factor: 14.808

3.  Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.

Authors:  John P Anderson; Donald E Walker; Jason M Goldstein; Rian de Laat; Kelly Banducci; Russell J Caccavello; Robin Barbour; Jiping Huang; Kristin Kling; Michael Lee; Linnea Diep; Pamela S Keim; Xiaofeng Shen; Tim Chataway; Michael G Schlossmacher; Peter Seubert; Dale Schenk; Sukanto Sinha; Wei Ping Gai; Tamie J Chilcote
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

Review 4.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria.

Authors:  Dennis W Dickson; Heiko Braak; John E Duda; Charles Duyckaerts; Thomas Gasser; Glenda M Halliday; John Hardy; James B Leverenz; Kelly Del Tredici; Zbigniew K Wszolek; Irene Litvan
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

5.  Repression of alpha-synuclein expression and toxicity by microRNA-7.

Authors:  Eunsung Junn; Kang-Woo Lee; Byeong Seon Jeong; Teresa W Chan; Joo-Young Im; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-23       Impact factor: 11.205

6.  Apoptosis signal-regulating kinase 1 modulates the phenotype of α-synuclein transgenic mice.

Authors:  Kang-Woo Lee; Jong-Min Woo; Joo-Young Im; Eun S Park; Liqiang He; Hidenori Ichijo; Eunsung Junn; M Maral Mouradian
Journal:  Neurobiol Aging       Date:  2014-07-31       Impact factor: 4.673

7.  Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons.

Authors:  Dilyan I Dryanovski; Jaime N Guzman; Zhong Xie; Daniel J Galteri; Laura A Volpicelli-Daley; Virginia M-Y Lee; Richard J Miller; Paul T Schumacker; D James Surmeier
Journal:  J Neurosci       Date:  2013-06-12       Impact factor: 6.167

8.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.

Authors:  Jia-Yi Li; Elisabet Englund; Janice L Holton; Denis Soulet; Peter Hagell; Andrew J Lees; Tammaryn Lashley; Niall P Quinn; Stig Rehncrona; Anders Björklund; Håkan Widner; Tamas Revesz; Olle Lindvall; Patrik Brundin
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

9.  Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex.

Authors:  Sonja Blumenstock; Eva F Rodrigues; Finn Peters; Lidia Blazquez-Llorca; Felix Schmidt; Armin Giese; Jochen Herms
Journal:  EMBO Mol Med       Date:  2017-05       Impact factor: 12.137

10.  Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene.

Authors:  Yixi Chen; Karamjit Singh Dolt; Marco Kriek; Terry Baker; Patrick Downey; Nicola J Drummond; Maurice A Canham; Ammar Natalwala; Susan Rosser; Tilo Kunath
Journal:  Eur J Neurosci       Date:  2018-12-21       Impact factor: 3.386

View more
  3 in total

Review 1.  Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.

Authors:  Matthew Upcott; Kirill D Chaprov; Vladimir L Buchman
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

Review 2.  Mitochondrial Dysfunction in Parkinson's Disease: From Mechanistic Insights to Therapy.

Authors:  Xiao-Yan Gao; Tuo Yang; Ying Gu; Xiao-Hong Sun
Journal:  Front Aging Neurosci       Date:  2022-06-20       Impact factor: 5.702

3.  Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.

Authors:  Elif Çınar; Banu Cahide Tel; Gürdal Şahin
Journal:  Balkan Med J       Date:  2022-08-29       Impact factor: 3.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.